Is Helix BioPharma Corp halal to invest in?

According to Musaffa's Shariah screening methodology, Helix BioPharma Corp (HBP.TO) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Helix BioPharma Corp a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Helix BioPharma Corp using these criteria to determine its compliance status.

Can Muslims buy shares of Helix BioPharma Corp?

Muslim investors may consider investing in Helix BioPharma Corp if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Helix BioPharma Corp classified as NOT HALAL?

Musaffa determines the Shariah status of Helix BioPharma Corp by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Helix BioPharma Corp updated?

The Shariah compliance status of Helix BioPharma Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Helix BioPharma Corp become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Helix BioPharma Corp?

You can check the latest Shariah compliance status of Helix BioPharma Corp on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

HBP.TO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 11, 2026

Report Source: 2026 2nd Quarter Report

Helix BioPharma Corp. Stock Analysis HBP.TO

Canada Health Care Micro Cap Report: Q2, 2026

Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company is headquartered in Toronto, Ontario. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The firm is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

Key Statistics of Helix BioPharma Corp (HBP.TO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

CAD1.58CAD1.58

Today's Open

CAD1.58

Volume

128.00

P/E Ratio (TTM)

52 Week Range

CAD0.84CAD5.40

Market Cap

155.81M

Avg. Volume

3474.56

Dividend Yield

Financial Metrics & Statements of Helix BioPharma Corp (HBP.TO)

FAQ's for Helix BioPharma Corp (HBP.TO)

According to Musaffa’s Shariah screening methodology, Helix BioPharma Corp (HBP.TO) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.